CHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically significant reduction in Alzheimer's ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

Vascular dementia is the second-most common form of dementia after Alzheimer's. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

Despite encouraging biomarker shifts, oral semaglutide failed to slow cognitive decline in early Alzheimer’s, leading to an early end of the trial extension.

NOVEMBER IS RECOGNIZED AS NATIONAL ALZHEIMER’S AWARENESS MONTH, A FIRST OF ITS KIND CLINICAL TRIAL IS CHANGING THE LIVES OF ...

A bill introduced in Congress aims to give older adults timely access to diagnostic tests that can detect dementia in its earliest stages.

As a constituent in Georgia 14th Congressional District, I would like to bring awareness to the recently introduced H.R. 6130 The Alzheimer’s Screening and Prevention (ASAP) Act . This legislation ...

experts comment on news from Novo Nordisk that semaglutide does not reduce Alzheimer’s Disease progression Prof Tara Spires-Jones, Director of the Centre for Discovery Brain Sciences at the University ...

Experts and those who have had to take care of loved ones with the disease shared how you can spot the signs. CHICAGO - Many families only see each other a few times a year. When everyone gathers, you ...

The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s ...

Healthier bodies with more muscle mass and less hidden belly fat are more likely to have healthier, youthful brains." ...

As families prepare for the busy holiday season, November’s recognition of National Family Caregivers Month serves as a ...